WO2005045432A3 - Method for distinguishing prognostically definable aml - Google Patents

Method for distinguishing prognostically definable aml Download PDF

Info

Publication number
WO2005045432A3
WO2005045432A3 PCT/EP2004/012367 EP2004012367W WO2005045432A3 WO 2005045432 A3 WO2005045432 A3 WO 2005045432A3 EP 2004012367 W EP2004012367 W EP 2004012367W WO 2005045432 A3 WO2005045432 A3 WO 2005045432A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognostically
definable
distinguishing
aml
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/012367
Other languages
French (fr)
Other versions
WO2005045432A2 (en
Inventor
Martin Dugas
Claudia Schoch
Alexander Kohlmann
Susanne Schnittger
Wolfgang Kern
Torsten Haferlach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Ludwig Maximilians Universitaet Muenchen LMU
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Ludwig Maximilians Universitaet Muenchen LMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH, Ludwig Maximilians Universitaet Muenchen LMU filed Critical F Hoffmann La Roche AG
Priority to EP04797513A priority Critical patent/EP1682895A2/en
Priority to US10/577,751 priority patent/US20070122814A1/en
Publication of WO2005045432A2 publication Critical patent/WO2005045432A2/en
Publication of WO2005045432A3 publication Critical patent/WO2005045432A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

Disclosed is a method for distinguishing prognostically definable AML subtypes with normal karyotype into different prognosis subsets in a sample by determining the expression level of markers, as well as a diagnostic kit and an apparatus containing the markers.
PCT/EP2004/012367 2003-11-04 2004-11-02 Method for distinguishing prognostically definable aml Ceased WO2005045432A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04797513A EP1682895A2 (en) 2003-11-04 2004-11-02 Method for distinguishing prognostically definable aml
US10/577,751 US20070122814A1 (en) 2003-11-04 2004-11-02 Methods for distinguishing prognostically definable aml

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025338.9 2003-11-04
EP03025338A EP1533618A1 (en) 2003-11-04 2003-11-04 Method for distinguishing prognostically definable AML

Publications (2)

Publication Number Publication Date
WO2005045432A2 WO2005045432A2 (en) 2005-05-19
WO2005045432A3 true WO2005045432A3 (en) 2005-08-04

Family

ID=34429267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012367 Ceased WO2005045432A2 (en) 2003-11-04 2004-11-02 Method for distinguishing prognostically definable aml

Country Status (3)

Country Link
US (1) US20070122814A1 (en)
EP (2) EP1533618A1 (en)
WO (1) WO2005045432A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015119570A1 (en) * 2014-02-07 2015-08-13 Agency For Science, Technology And Research Prl-3 as a biomarker for the prognosis of cancer and a target for therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043676A2 (en) * 1999-04-09 2000-10-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US20030011943A1 (en) * 2001-07-12 2003-01-16 Webb Patrick Rush Overlaid lead giant magnetoresistive head with side reading reduction
WO2003039443A2 (en) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
WO2003083140A2 (en) * 2002-03-22 2003-10-09 St.Jude Children's Research Hospital, Inc. Classification and prognosis prediction of acute lymphoblasstic leukemia by gene expression profiling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69527585T2 (en) * 1994-06-08 2003-04-03 Affymetrix, Inc. Method and device for packaging chips
JP4540754B2 (en) * 1996-06-04 2010-09-08 ユニバーシティ オブ ユタ リサーチ ファウンデーション Monitoring of hybridization during PCR

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043676A2 (en) * 1999-04-09 2000-10-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US20030011943A1 (en) * 2001-07-12 2003-01-16 Webb Patrick Rush Overlaid lead giant magnetoresistive head with side reading reduction
WO2003039443A2 (en) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
WO2003083140A2 (en) * 2002-03-22 2003-10-09 St.Jude Children's Research Hospital, Inc. Classification and prognosis prediction of acute lymphoblasstic leukemia by gene expression profiling

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALIZADEH A ET AL: "THE LYMPHOCHIP: A SPECIALIZED CDNA MICROARRAY FOR THE GENOMIC-SCALE ANALYSIS OF GENE EXPRESSION IN NORMAL AND MALIGNANT LYMPHOCYTES", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, BIOLOGICAL LABORATORY, COLD SPRING HARBOR, NY, US, vol. 64, no. 1, 1999, pages 71 - 78, XP001099007, ISSN: 0091-7451 *
BOISSEL N ET AL: "Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy", LEUKEMIA (BASINGSTOKE), vol. 16, no. 9, September 2002 (2002-09-01), pages 1699 - 1704, XP002272117, ISSN: 0887-6924 *
DUGAS M ET AL: "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 15, no. 12, December 2001 (2001-12-01), pages 1805 - 1810, XP002263731, ISSN: 0887-6924 *
DUGAS MARTIN ET AL: "Impact of integrating clinical and genetic information.", IN SILICO BIOLOGY, vol. 2, no. 3, 2002, pages 383 - 391, XP001179418, ISSN: 1386-6338 (ISSN print) *
GOLUB T R ET AL: "Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 531 - 537, XP002207658, ISSN: 0036-8075 *
KOHLMANN A ET AL: "MOLECULAR CHARACTERIZATION OF ACUTE LEUKEMIAS BY USE OF MICROARRAY TECHNOLOGY", GENES, CHROMOSOMES & CANCER, XX, XX, vol. 37, no. 4, August 2003 (2003-08-01), pages 396 - 405, XP008025253 *
SCHNITTGER S ET AL: "Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML", LEUKEMIA (BASINGSTOKE), vol. 14, no. 5, May 2000 (2000-05-01), pages 796 - 804, XP002272116, ISSN: 0887-6924 *

Also Published As

Publication number Publication date
EP1533618A1 (en) 2005-05-25
EP1533618A8 (en) 2006-02-01
EP1682895A2 (en) 2006-07-26
US20070122814A1 (en) 2007-05-31
WO2005045432A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
SG144729A1 (en) Method for controlling the microbiological quality of an aqueous medium and kit therefor
WO2006023769A3 (en) Determining data quality and/or segmental aneusomy using a computer system
WO2002040710A3 (en) Method for detecting methylation states for a toxicological diagnostic
WO2006012646A3 (en) Amacr cancer markers
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2007106309A3 (en) Method of identifying and localizing drainage tile problems
EP1791956A4 (en) Oligonucleotide for detection of microorganism diagnostic kits and methods for detection of microorganis using the oligonucleotide
WO2007088355A3 (en) Sepsis test
WO2005106036A3 (en) Methods and compositions for assaying analytes
PT1812590E (en) Methods and reagents for the detection of melanoma
GB2410798A (en) Methods detecting, characterising and monitoring hydrocarbon reservoirs
WO2005064307A3 (en) Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
EP2039782A3 (en) Method and apparatus for judging the presence or absence of cancer cell
WO2005021745A8 (en) Hepatocellular cancer-associated gene
WO2005045432A3 (en) Method for distinguishing prognostically definable aml
WO2006129036A3 (en) Light-emitting biomarker
AU4632396A (en) Method of determining the hepatic status of an individual, including a liver transplant recipient
WO2002103043A3 (en) Method for the specific fast detection of bacteria which is harmful to beer
WO2005043168A3 (en) Method for distinguishing aml-specific flt3 length mutations from tkd mutations
WO2005043162A8 (en) Method for distinguishing mll-ptd-positive aml from other aml subtypes
WO2005043164A3 (en) Method for distinguishing cbf-positive aml subtypes from cbf-negative aml subtypes
WO2004084708A3 (en) Finding usable portion of sigmoid curve
EP2455495A3 (en) Instrument for detecting bacteria, method of detecting bacteria and kit for detecting bacteria
WO2002004683A3 (en) Method of detecting an increased susceptibility to breast cancer
EP2380978A3 (en) Gene group applicable to cancer prognostication

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004797513

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004797513

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007122814

Country of ref document: US

Ref document number: 10577751

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10577751

Country of ref document: US